Nishat Shama

Nishat Shama

Auto-generated profile, based on publicly available information

Nishat Shama

Henry Ford Jackson Hospital, Michigan, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Journal of Primary Care & Community Health
Verified
Journal Article
Open access
VJVikash Jaiswal
Vikash Jaiswal
GNGaurav Nepal
Gaurav Nepal
PDPatricia Dijamco
Patricia Dijamco
AIAngela Ishak
Angela Ishak
MDMehak Dagar
Mehak Dagar
AJAkash Jaiswal
Akash Jaiswal
Introduction: COVID-19 vaccines became available after being carefully monitored in clinical trials with safety and efficacy on the human body. However, a few recipients developed unusual side effects, including cerebral venous sinus thrombosis (CVST). We aim to systematically review the baseline features, clinical characteristics, treatment, and outcomes in patients developing CVST post-COVID-19 vaccination. Methods: This study was conducted according to the PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analysis) 2020 guideline. Investigators independently searched PubMed, Embase, and Google Scholar for English language articles published from inception up until September 10, 2021, reporting the incidence of CVST post-COVID-19 vaccines. We analyzed CVST patients’ baseline data, type of vaccines, clinical findings, treatment, and outcomes. Our systematic review process yielded patient-level data. Result: The final analysis included 25 studies that identified 80 patients who developed CVST after the COVID-19 vaccination. Of the 80 CVST cases, 31 (39.24%) patients died. There was no significant relationship between mortality and age ( P = .733), sex ( P = .095), vaccine type ( P = .798), platelet count ( P = .93), and comorbidities such as hypertension ( P = .734) and diabetes mellitus ( P = .758). However, mortality was associated with the duration of onset of CVST symptoms after vaccination ( P = .022). Patients with CVST post-COVID-19 vaccination were more likely to survive if treated with an anticoagulant ( P = .039). Patients who developed intracranial hemorrhage ( P = .012) or thrombosis in the cortical vein ( P = .021) were more likely to die. Conclusion: COVID-19 vaccine-associated CVST is associated with high mortality rate. Timely diagnosis and management can be lifesaving for patients.

10 February 2022 in Rheumatology
Verified
Journal Article
Open access
PDF file
MSManoj Reddy Somagutta
Manoj Reddy Somagutta
NSNishat Shama
Nishat Shama
MPMaria Lourdes Pormento
Maria Lourdes Pormento
RJRavi Pankajbhai Jagani
Ravi Pankajbhai Jagani
NNNgaba Ngardig Neguemadji
Ngaba Ngardig Neguemadji
MJMolly Sanjay Jain
Molly Sanjay Jain
Statins are a class of lipid-lowering medications used worldwide by millions of people and are safe for frequent use in most patients. However, they cause necrotizing autoimmune myopathy in some patients. We reviewed case reports of 80 patients from 2010 to present diagnosed with statin-induced necrotizing autoimmune myopathy (SINAM), aiming to analyze the clinical, physiological, serologic characteristics and outcomes of SINAM. The mean age of these patients was 66 ±9.4, the majority being male (61.3%). All patients reported proximal muscle weakness, and a few had myalgias, extra-muscular symptoms such as dysphagia, and pulmonary complications. Most of the patients were on atorvastatin, simvastatin, or rosuvastatin. The mean creatine kinase was 10,094.2 ±7,351.7 U/l, and anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase enzyme was positive for 93.8% of patients. The majority of patients were started on steroids; other treatments were also used. Prompt cessation of statins and initiation of immunosuppressants reduced morbidity and mortality.

20 November 2022 in Korean Journal of Family Medicine
Verified
Journal Article
Open access
PDF file
MSManoj Kumar Reddy Somagutta
Manoj Kumar Reddy Somagutta
UUUtkarsha Uday
Utkarsha Uday
NSNishat Shama
Nishat Shama
NBNarayana Reddy Bathula
Narayana Reddy Bathula
SPSiva Pendyala
Siva Pendyala
NNNgaba Ngardig Neguemadji
Ngaba Ngardig Neguemadji
Background: The use of euglycemic diabetic ketoacidosis (EDKA) related to sodium-glucose cotransporter 2 inhibitors (SGLT2i) use in people with diabetes has been increasingly reported. The causes are multifactorial, and dietary changes in SGLT2i users were observed to trigger EDKA. A ketogenic diet or very low-carbohydrate diet (VLCD) enhances body ketosis by breaking down fats into energy sources, causing EDKA. This study aimed to understand the patient specific risk factors and clinical characteristics of this cohort.Methods: Several databases were carefully analyzed to understand the patients’ symptoms, clinical profile, laboratory results, and safety of dietary changes in SGLT2i’s. Thirteen case reports identifying 14 patients on a ketogenic diet and SGLT2i’s diagnosed with EDKA were reviewed.Results: Of the 14 patients, 12 (85%) presented with type-2 diabetes mellitus (DM) and 2 (15%) presented with type-1 DM. The duration of treatment with SGLT2i before the onset of EDKA varies from 1 to 365 days. The duration of consuming a ketogenic diet or VLCD before EDKA onset varies from 1 to 90 days, with over 90% of patients hospitalized <4 weeks after starting the diet. At presentation, average blood glucose was 167.50±41.80 mg/dL, pH 7.10±0.10, HCO3 8.1±3.0 mmol/L, potassium 4.2±1.1 mEq/L, anion-gap 23.6±3.5 mmol/L, and the average hemoglobin A1c was 10%±2.4%. The length of hospital stay ranged from 1 to 15 days. None of the patients were reinitiated on SGLT2i’s, and 50% (2/4) of the patients reported were on the ketogenic diet or VLCD upon patient questioning.Conclusion: Despite the popularity of the ketogenic diet and VLCD for weight loss, their use in diabetics taking SGLT2i’s is associated with EDKA. Physicians should educate patients with diabetes taking SGLT2i’s about the risk of EDKA. In addition, patients should be encouraged to include their physicians in any decision related to significant changes in diet or exercise routines. Further research is needed to address if SGLT2i’s should be permanently discontinued in patients with diabetes on SGLT2i and whether the ketogenic diet developed EDKA.

9 August 2023 in Cureus
Verified
Journal Article
Open access
PDF file
PDPriyata Dutta
Priyata Dutta
PSPrince Shah-Riar
Prince Shah-Riar
SBSumaita Sadida Bushra
Sumaita Sadida Bushra
SHSharar Naiarin Haque
Sharar Naiarin Haque
ZRZahin Islam Rafa
Zahin Islam Rafa
BDBarna Dam
Barna Dam
Eosinophilic esophagitis (EoE) is a chronic immune-mediated condition characterized by inflammation and eosinophilic accumulation of the esophagus, resulting in dysphagia and food impaction. While the exact etiology of EoE remains unclear, it is believed to be triggered by food allergens and dynamic environmental factors, resulting in various clinical manifestations, from inflammation to fibrosis. Although clinical presentation varies with age, the number of eosinophils in esophagogastroduodenal endoscopy remains the diagnostic gold standard. While diet elimination, proton pump inhibitors (PPIs), topical corticosteroids, and biological therapy are promising treatment options for EoE, there are insufficient data to determine the optimal therapeutic treatment approach. Combination therapies - the use of dietary therapies in conjunction with other treatment modalities, such as PPIs, topical corticosteroids, or biologic agents - have also emerged as a potential management strategy for EoE. In this systematic review, we attempt to highlight the recent advances in EoE therapies and provide updated guidance to their management. From 2017 to 2022, we conducted a comprehensive electronic search of PubMed (MEDLINE) using specific keywords related to our objective and eventually included a total of 44 articles.

25 March 2025 in JACC: Advances
Verified
Journal Article
Open access
RTRashmi Thapa
Rashmi Thapa
KLKyla M. Lara-Breitinger
Kyla M. Lara-Breitinger
FLFrancisco Lopez-Jimenez
Francisco Lopez-Jimenez
NSNishat Shama
Nishat Shama
AEAlexander C. Egbe
Alexander C. Egbe
LBLuke Burchill
Luke Burchill
Obesity is prevalent among patients with adult congenital heart disease (ACHD) and contributes to adverse cardiovascular outcomes. There is a paucity of data regarding glucagon-like peptide-1 receptor agonists (GLP-1 RA) for weight loss in patients with ACHD. The purpose of this study was to assess the effect, safety, and outcomes of GLP-1 RA among patients with ACHD. This is a retrospective cohort study of patients with ACHD at Mayo Clinic (01/2013-01/2024) who were prescribed semaglutide or liraglutide. The primary endpoint was weight loss. Secondary endpoints were changes in New York Heart Association class, hemoglobin A1c, estimated glomerular filtration rate, and safety endpoints of renal adverse event, hypoglycemia, hospitalization/drug discontinuation due to side effects. Seventy patients received GLP-1 RA over a mean duration of 21 ± 20 months. Majority (85.7%) had moderate/severe complexity congenital heart disease. Weight loss >5% was achieved in 30 (42.9%) patients. Patients with body mass index ≥35 kg/m2 were more likely to achieve weight loss >5% [66.7% vs 40%, P = 0.027]. Younger age resulted in improved weight loss of 0.17 kg per 1-year age difference (P = 0.014). Hemoglobin A1c lowered by a mean of 0.6% (P = 0.054). There were no significant changes in New York Heart Association class or estimated glomerular filtration rate. One-third of patients experienced side effects, mostly from gastrointestinal intolerance (20%); 11.4% discontinued the medication due to side effects. GLP-1 RAs are safe and effective for weight loss in patients with ACHD with beneficial effects on glycemic control.

6 July 2026 in Public Health and Epidemiology: Open Access
Verified
Journal Article
Closed access
KSKartikeya Srivastava
Kartikeya Srivastava
NSNishat Shama
Nishat Shama
AMAnza Muhammad
Anza Muhammad
TSThirumurugan Sivakumaar
Thirumurugan Sivakumaar
MBMrinal Bhandari
Mrinal Bhandari
LKLaiba Khalid
Laiba Khalid
Background Thrombotic complications remain an important concern after transcatheter aortic valve replacement (TAVR), particularly because leaflet thrombosis may impair prosthetic valve function and contribute to adverse clinical outcomes. Patients with pre-existing hypercoagulable disorders may represent a higher-risk subgroup, yet their outcomes after TAVR have not been well characterized. We evaluated whether selected hypercoagulable conditions were associated with worse inpatient outcomes following TAVR. Methods The National Inpatient Sample was queried from 2018 through 2020 to identify adult hospitalizations involving TAVR. Hypercoagulable status was defined by the presence of systemic lupus erythematosus, antiphospholipid antibody syndrome, Factor V Leiden mutation, lupus anticoagulant syndrome, or prothrombin gene mutation using ICD-10-CM codes. Among 205,565 TAVR hospitalizations, 1,480 involved patients with one or more of these conditions. Baseline characteristics were compared using Mann-Whitney U and Chi-square testing. Multivariable logistic regression was then used to assess the relationship between hypercoagulable status and inpatient clinical outcomes, with statistical significance defined as p < 0.05. Results The study cohort had a median age of 80 years (IQR 73–85), and 43.9% were female. After adjustment, the presence of a hypercoagulable condition was not independently associated with a statistically significant increase in any primary or secondary inpatient outcome. However, several clinically relevant trends were observed. Patients with hypercoagulable states had numerically higher odds of all-cause mortality (OR 1.68) and major adverse cardiovascular events (OR 1.36). They also demonstrated higher odds of prosthetic valve leakage (aOR 1.14) and prosthetic valve thrombosis (aOR 5.03), although these associations did not reach statistical significance. Conversely, post-procedural pacemaker implantation (OR 0.86) and cerebrovascular accident (OR 0.72) were numerically less frequent in the hypercoagulable group. Conclusion In a national cohort of patients undergoing TAVR, underlying hypercoagulable disorders were not significantly associated with worse adjusted inpatient outcomes. Nevertheless, the direction of effect for mortality, MACE, prosthetic valve leakage, and particularly prosthetic valve thrombosis suggests a possible signal toward increased thrombotic and adverse cardiovascular risk. These findings highlight the need for larger studies with more granular clinical and antithrombotic data to better define post-TAVR risk and management strategies in patients with hypercoagulable conditions.